Extensive studies have validated the c-MET RTK and its downstream pathways including mTOR, Akt, STAT3, ERK1/2, MAPK, and HSP90 as OC in vivo anti-BC molecular targets [7,9,18,23,26,33,39]. This evidence concerns the gene MAPK3 and breast cancer.